We would love to hear your thoughts about our site and services, please take our survey here.
"Jackdaw, if the current vaccines had a strong memory effect, we wouldn't need an annual booster." First, the immune memory is how vaccinations work at all, so existing vaccines obviously stimulate memory T-cells. How strong? Well, the issue with renewed annual shots is not necessarily the loss of immune memory, although it could be, but more usually the incessant mutation of the virus. If the mutation is sufficiently diverse then the memory of the previous version is only of so much use. Obviously, we hope that Scancell's vaccines will be less conservative in their targetting of antigen!
"What is clear is that the current vaccines do not have a strong memory effect." Could be, but I haven't seen clear evidence.
"Couple that with the fact that Covidity targets N Protein epitopes which is a protein well preserved in variants, it also promises to be effective against new variants coming along." Could well prove to be true. Let's hope so.
They may well be but RENE have moved a bit away from stem cells in the last two years. Perhaps something else is also the future?
We'll probably see Novo buying again. Good climate for them.
A highly effective malaria vaccine has been recommended for widespread use by the World Health Organization.
The R21/Matrix-M vaccine, developed by the University of Oxford, is only the second malaria vaccine to be recommended by the WHO. It is the first to meet the WHO’s target of 75% efficacy. Malaria, a mosquito-borne disease, claims half a million lives every year and mostly affects children under the age of five, and pregnant women. “As a malaria researcher, I used to dream of the day we would have a safe and effective vaccine against malaria. Now we have two,” said Dr Tedros Adhanom Ghebreyesus, director general of the WHO. Demand for vaccines is huge. However, available supplies of the RTS,S vaccine, the first malaria vaccine approved by the WHO in 2021, are limited. A second WHO-recommended vaccine is expected “to protect more children faster, and to bring us closer to our vision of a malaria-free future,” said Tedros.
The RTS,S vaccine will be available in some African countries in early 2024 and the R21 malaria vaccine is expected to become available to countries in mid-2024. The world’s largest vaccine manufacturer by doses – the Serum Institute of India – is already lined up to make more than 100m doses a year and plans to scale up to 200m a year, the BBC reported. Each dose costs between $2 and $4; four doses are needed per person. That is about half the price of RTS,S. So far, there are only 18m doses of RTS,S. (Guardian)
Keep calm & Carry on?
From Kernowlad: "And it continues. I wish I had Jackdaw's optimism but I don't.
Unless they pull something out of the bag at the interims this will continue to drift downwards - or even faster possibly.
Where is the value?"
I think they did?
...or someone wants in cheap?
Yes, obviously high risk but, if it comes good, any deal could be huge.
"...It could easily be at new 3 year highs by the end of the week…..those who keep selling because they expect a pullback because “thats what usually happens’ may miss out…...." Yes. And now they are being encouraged because someone still needs to buy? Acceleration after lunch IMO.